Navigation Links
Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
Date:11/15/2011

PERATING EXPENSES:Research and development2,284,3833,452,762General and administrative1,109,3821,381,776Total operating expenses3,393,7654,834,538Loss from operations(3,366,548)(4,618,391)OTHER INCOME (EXPENSE):Investment income15,04020,375Interest expense(2,973)(2,304)Total other income, net12,06718,071NET LOSS$
(3,354,481)$   (4,600,320)Basic and diluted net loss per common share$
(0.10)$
(0.39)Weighted average number of common
shares outstanding used in
computing basic and diluted net loss
per common share34,900,59111,730,308PALATIN TECHNOLOGIES, INC.

and SubsidiaryConsolidated Balance Sheets(unaudited)September 30,
2011June 30,
2011ASSETSCurrent assets:  Cash and cash equivalents$
4,883,613$
8,869,639  Accounts receivable-131,149  Prepaid expenses and other current assets403,062261,947Total current assets15,286,67519,262,735Property and equipment, net1,050,3291,305,331Restricted cash350,000350,000Other assets155,069254,787Total assets$
,842,073$
21,172,853LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:  Capital lease obligations$
30,078$
34,923  Accounts payable 336,206496,908  Accrued compensation-374,094  Unearned revenue18,88846,105  Accrued expenses1,271,9701,854,007Total current liabilities1,657,1422,806,037Capital lease obligations 36,77542,186Deferred rent100,589132,855Total liabilities1,794,5062,981,078Stockholders' equity:  Preferred stock of $.01 par value – authorized 10,000,000 shares;Series A Convertible; issued and outstanding 4,997 shares
as of September 30, 2011 and June 30, 2011, respectively5050  Common stock of $.01 par value – authorized 100,000,000
shares; issued and outstanding 34,900,591 as of
September 30, 2011 and June 30, 2011, respectively349,006349,006  Additional paid-in capital240,043,099239,832,826  Accumulated deficit (225,344,588)(221,990,107)Total stockholders' equity15,047,
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
2. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
3. Palatin Technologies to Report Fiscal Year 2009 First Quarter Results; Conference Call and Webcast on November 17, 2008
4. Palatin Technologies Receives Notification Letter from NYSE Alternext US
5. Palatin Technologies to Report Fiscal Year 2009 Second Quarter Results; Conference Call and Webcast on February 17, 2009
6. Palatin Technologies Listing Compliance Plan Accepted by NYSE Alternext US
7. Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate
8. Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration
9. Palatin Technologies, Inc. to Raise $3.1 Million in Registered Direct Offering
10. Palatin Technologies to Present at the Rodman & Renshaw 11th Annual Global Investment Conference
11. Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year 2009 Results; Teleconference and Webcast to be held on September 8, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... (PRWEB) May 17, 2013 Rust removal is ... and non-metal home items could be damaged. To help rust ... use of its no-scrubbing rust remover it called ... able available with 10% discount. , My Cleaning Products explained ... corroding them or by staining them. The first one, ...
(Date:5/16/2013)... 16, 2013 ISPE ... Myers, CAE, to the newly created position of ... role, Myers will be responsible for stimulating ISPE’s ... strategies, advancing the Society’s Member-led and staff-driven business ... to refine organizational, membership and product marketing. , ...
(Date:5/16/2013)... May 16, 2013 Cambridge Healthtech Institute ... August 19-23, 2013 at the Renaissance Waterfront Hotel in ... provide a close-up look at the current strategies and ... bottom-line quality. Leaders in the field will reveal ... produce biopharmaceuticals with greater specificity and efficiency. , “In ...
(Date:5/16/2013)... 16, 2013 Scientists at the Center for ... , and the California -based biopharmaceutical ... novel therapy for reversing memory decline in mice with ... significant cognitive improvement in advanced stage AD mice. The ... reversing cognitive decline for advanced stage AD mice, and ...
Breaking Biology Technology:Organic-Based Rust Remover Cuts Down Price by 10%, My Cleaning Products Details Mechanics How to Get the Discount 2ISPE Names Barbara A. Myers, CAE, as Vice President of Professional Development 2The 2013 Bioprocessing Summit to Bring Together International Leaders to Discuss Today's Bioprocess Issues From Cell Line Selection to Manufacturing in Boston, MA 2Elevation of Brain Magnesium Reverses Memory Deficits in Alzheimer Mice 2Elevation of Brain Magnesium Reverses Memory Deficits in Alzheimer Mice 3
... Excellence and Patient Ease-of-Use, BROOKFIELD, Wis., April ... won the 2008 Medical Design Excellence Awards (MDEA) ... Genesis DM won in the,rehabilitation and assistive-technology products ... monitoring device is,ideal for both the patient and ...
... Replikins Ltd. has found that the,Replikin Count(TM) of the ... (plus/minus 1.4), its highest level since the 1918 H1N1,pandemic ... of a particular,influenza strain, indicating rapid replication of the ... by an outbreak of the specific,strain. The current increase ...
... 2008 A,cross-disciplinary research team at the University of ... drug research platform can,produce the chemical reactions needed to ... on a tiny "biochip" created to mimic,the environment within ... This means that the researchers can proceed to the ...
Cached Biology Technology:Honeywell HomMed Wins 2008 Medical Design Excellence Award for Genesis DM Remote Care Device 2Honeywell HomMed Wins 2008 Medical Design Excellence Award for Genesis DM Remote Care Device 3H1N1 Influenza Virus With Highest Replikin Count(TM) Since the 1918 Pandemic Identified in the U.S. and Austria 2U-Md. Researchers Report Advance in Biological Microfactories for Drug Research 2U-Md. Researchers Report Advance in Biological Microfactories for Drug Research 3U-Md. Researchers Report Advance in Biological Microfactories for Drug Research 4
(Date:5/17/2013)... of all ages will celebrate the science and ... our daily lives during the inaugural Atlanta Science ... educators from local museums, corporations, K-12 schools and ... different events for children and adults at venues ... . , The annual Atlanta Science Festival ...
(Date:5/17/2013)... of American Societies for Experimental Biology (FASEB) released a ... (NIH) funding trends highlighting the devastating impact of sequestration ... FASEB analysis follows a May 15th Senate Appropriations Committee ... testified that the $1.6 billion cut the agency sustained ... substantial impact on the scientific community." , According ...
(Date:5/16/2013)... to a fast food restaurant had a higher body ... from fast food, according to researchers at The University ... was particularly strong among those with a lower income. ... American Journal of Public Health indicates higher ... restaurant, and among lower-income African-Americans, the density, or number, ...
Breaking Biology News(10 mins):First Atlanta Science Festival set for 2014 2Body mass index of low income African-Americans linked to proximity of fast food restaurants 2Body mass index of low income African-Americans linked to proximity of fast food restaurants 3
... famed starship Enterprise would deploy a deflector shield to evade ... molecular force field of their own to fend off treatments ... found a chink in their armor. , The cells churn ... protective barrier that deflects damage from radiation or chemotherapy and ...
... study of more than 68,000 infants published in this ... Rotateq demonstrated that it can safely prevent 98 percent ... account for 2 million hospital visits and 500,000 pediatric ... largest pre-licensure vaccine clinical trials ever conducted worldwide, research ...
... the University of Pennsylvania, demonstrate that biodegradable nano-particles ... killing human breast tumors. The unique properties ... allow them to deliver two distinct drugs, paclitaxel, ... such as Taxol, and doxorubicin directly to tumors ...
Cached Biology News:Molecular force field helps cancer cells defend against attack 2Molecular force field helps cancer cells defend against attack 3New vaccine for condition that kills 500,000 children a year 2New vaccine for condition that kills 500,000 children a year 3Nano-particles effective in killing cancer with one-two punch of chemotherapeutics 2
Rat polyclonal to acetyl Salicylic Acid ( Abpromise for all tested applications)....
Rabbit polyclonal to UBC12 (rating: ****) ( Abpromise for all tested applications). Antigen: Synthetic peptide: RGGYIGSTYFER, corresponding to amino acids 169-180 of UBC12 Entrez Gene ID: 90...
...
... Product Mouse monoclonal [SPM278] to ... Small cell lung carcinoma N592 live cells ... with Human. Not yet tested in other ... of the major glycoproteins of basement membrane, ...
Biology Products: